Molnupiravir

Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

Product Specifications

CAS Number

[2492423-29-5]

Product Name Alternative

EIDD-2801; MK-4482

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Influenza Virus; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/eidd-2801.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C)C)=O)O1)C=C2)NC2=NO

Molecular Formula

C13H19N3O7

Molecular Weight

329.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11 (515) . pii: eaax5866.|[2]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.